BEAM Stock — Beam Therapeutics Inc.: Cash, EV, Pipeline

Share price

$24.95

Market cap

$2,577.0M

Cash

$1,152.9M

Enterprise value

$1,524.4M

Balance sheet

Cash	$1,152.9M
Debt	$100.3M
Net cash	$1,052.6M
Enterprise value	$1,524.4M
Basic shares	103.3M shares
Fully diluted shares	123.0M shares
Fully diluted market cap	$3,069.9M
Cash per share	$11.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BEAM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	BEAM-201	Phase 2	Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia	—
Feb 10 - Mar 23	BEAM-301: Single dose of BEAM-301 administered by IV	Phase 2	Glycogen Storage Disease Type Ia	—
Mar 14 - Apr 25	BEAM-101	Phase 2	Sickle Cell Disease	—
Jun 12 - Jul 24	BEAM-302	Phase 2	Alpha 1-Antitrypsin Deficiency	—
Jul 11 - Aug 22	Allogeneic anti-CD7 CAR-T cells (BEAM-201)	Phase 1	T-Cell Acute Lymphoblastic Leukemia/Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ristocel

Phase 1 · Active Modality: ex vivo autologous HSC base editing

Aliases risto-cel, formerly BEAM-101

Target HBG1/HBG2

Indications

Sickle cell disease (SCD) (Phase 1)

Catalysts

— as early as year-end 2026

Status note Lead program; Phase 1/2 BEACON trial ongoing. Base edits mimic hereditary persistence of fetal hemoglobin (HPFH) SNPs to raise HbF. One patient death reported (respiratory failure, 4 months post-infusion). In vivo HSC-targeted LNP is the next-wave approach for SCD (lead optimization).

BEAM-302

Phase 1 · Active Modality: in vivo LNP base editing (liver-targeted)

Target SERPINA1

Indications

Alpha-1 antitrypsin deficiency (AATD) (Phase 1)

Status note Corrects the E342K (PiZZ) mutation in a one-time treatment. Phase 1/2 open-label trial ongoing (Part A lung disease, Part B liver disease). FDA alignment on a potential accelerated approval pathway based on AAT biomarkers over 12 months; dose selection for registrational development to be finalized on trial data.

BEAM-301

Phase 1 · Active Modality: in vivo LNP base editing (liver-targeted)

Target G6PC

Indications

Glycogen storage disease type 1a (GSDIa) (Phase 1)

Catalysts

— 2026

Status note Corrects the R83C mutation in G6PC; open-label, multi-cohort single-ascending-dose Phase 1/2 in the U.S.

BEAM-304

Preclinical · Active Modality: in vivo LNP base editing (liver-targeted)

Target PAH

Indications

Phenylketonuria (PKU) (Preclinical)

Catalysts

— 2026

Status note Newly announced; initial development targets the two most prevalent PAH variants (R408W first).

BEAM-103

Phase 1 · Active Modality: anti-CD117 monoclonal antibody

Target CD117

Indications

not disclosed (Stage not disclosed)

Status note Enables the ESCAPE platform (non-genotoxic conditioning); Phase 1 healthy volunteer trial, dosing completion expected 1H 2026.

Pfizer collaboration development candidate (undisclosed)

Stage not disclosed · Active Modality: in vivo base editing (liver-targeted)

Partnerships Pfizer: exclusive worldwide license opt-in exercised December 2025 on a liver-targeted development candidate from the 2021 research collaboration (three rare-genetic-disease targets)

Status note Pfizer opted in at completion of the 4-year research term; no target or stage disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	BEAM-201
Lead indication	Lymphoblastic Lymphoma
Lead phase	Phase 2
Active trials	6
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05885464	Phase 2	Active, not recruiting	Sponsor	BEAM	—	Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia	—
NCT06735755	Phase 2	Recruiting	Sponsor	BEAM	—	Glycogen Storage Disease Type Ia	—
NCT05456880	Phase 2	Active, not recruiting	Sponsor	BEAM	—	Sickle Cell Disease	—
NCT06389877	Phase 2	Recruiting	Sponsor	BEAM	—	Alpha 1-Antitrypsin Deficiency	—
NCT07304791	Phase 1	Recruiting	Sponsor	BEAM	—	Healthy Subjects; Healthy Participant Study	—
NCT07373639	Not disclosed	Recruiting	Sponsor	BEAM	—	Hemoglobinopathy; Sickle Cell Disease	—
NCT06934382	Phase 1	Recruiting	Collaborator	Stephan Grupp MD PhD	—	T-Cell Acute Lymphoblastic Leukemia/Lymphoma	—
NCT06071377	Not disclosed	Recruiting	Collaborator	National Alliance for Sickle Cell Centers	—	Sickle Cell Trait	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 8 active trials for Beam Therapeutics Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	570,394	no change	0.17%	2026-08-14
ADAR1 Capital Management	0	-1,446,375	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BEAM — Beam Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders